Trial Profile

A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amivantamab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms OrigAMI-1
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

10 Jan 2026 According to Johnson & Johnson media release, data from this study were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium.
10 Jan 2026 Results published in the Media Release
22 Jun 2025 Planned End Date changed from 27 Apr 2027 to 21 May 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com